RespiriTB

Progress new assets (one pre-new molecular entity and one first-time-in-human start) for tuberculosis that act synergistically with bedaquiline, cytochrome bc or cytochrome bd inhibitors

keywords: IMI projects Antimicrobial resistance Infectious diseases AMR Accelerator Conducting clinical trials